Results 41 to 50 of about 317,965 (247)

Sustained Therapeutic Efficacy of Intravenous Plasminogen Concentrate in Pediatric Patients With Type 1 Plasminogen Deficiency: An Analysis of Dosing Parameters and Clinical Outcomes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Type 1 plasminogen deficiency (PLGD‐1) is an ultra‐rare autosomal recessive disorder caused by variants in the PLG gene and affects approximately 1.6 individuals per million. The condition is characterized by decreased plasminogen levels and impaired function, resulting in fibrin‐rich lesions on mucous membranes throughout the body.
Charles Nakar, Karen Thibaudeau, Mary Mathias, Heather McDaniel, Madlen Reschke, Klaus Tenbrock, Joseph M. Parker, Amy Shapiro   +7 more
wiley   +1 more source

Rational Use of Herbal Products in Pediatric Patients Treated With Anticancer Drugs in the European Union

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot, Mathieu Corvaisier, Laurence Spiesser‐Robelet, Mylène Duplan, Isabelle Pellier, Delphine Bourneau‐Martin, Séverine Derbré   +6 more
wiley   +1 more source

Association of factor V deficiency with factor V HR2.

Haematologica, 2004
Factor V HR2 possesses decreased co-factor activity to activated protein C and an increased ratio of factor V1 to factor V2. Factor V HR2 is associated with a mild increase in the risk of venous thromboembolism although not all studies concur on this point.Inconsistencies in results of the epidemiological studies may stem from a failure to identify ...
E.M. Faioni, G. Castaman, D. Asti, F. Lussana, F. Rodeghiero   +4 more
openaire   +2 more sources

Guidelines for Pediatric Radiotherapy Simulation: A Report From the Children's Oncology Group Radiation Oncology Discipline

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric radiation therapy presents unique challenges compared to adult treatments, including those of immobilization, potential need for sedation, and the critical importance of accurate, reproducible positioning. Additionally, heightened attention to imaging doses is necessary to minimize long‐term toxicity in survivors.
Parham Alaei, Stephen Mihalcik, Sujith Baliga, Young Kwok, Dana Casey, Eric Ehler, Christiane Burton, John C. Breneman, Daphne A. Haas‐Kogan, Suzanne L. Wolden, Arnold C. Paulino, Nadia N. Laack, Natia Esiashvili, Sarah Milgrom, Christine Hill‐Kayser, Thomas J. Fitzgerald, John A. Kalapurakal, Chia‐Ho Hua   +17 more
wiley   +1 more source

Personalized Zebrafish Models for Fusion‐Positive Pediatric Sarcomas

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Clinical sequencing efforts have revolutionized our approaches to categorizing pediatric cancers in real time. This has dramatically improved our ability to profile pediatric tumors, identify actionable vulnerabilities, and influence clinical care.
Lisa H. Hall, Emma N. Harrison, Genevieve C. Kendall   +2 more
wiley   +1 more source

Managing Parahemophilia: A Rare Coagulation Disorder - Case Report and Review

Clinical Pediatric Hematology-Oncology
A 5-month-old male child was admitted with cough and fever, during which excessive bleeding occurred from a venipuncture site. Born from a third-degree consanguineous marriage, the child was developmentally normal.
Sanghamitra Ray, Nidhi Chopra, Sumit Mehndiratta, Prashant Prabhakar, Amitabh Singh   +4 more
doaj   +1 more source

The Role of “Adult‐Onset” Cancer Predisposition Genes in Pediatric Cancer: A Comprehensive Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Current literature estimates that 10% of pediatric cancers are caused by pathogenic or likely pathogenic (P/LP) germline variants in cancer predisposition genes (CPGs). Variants in CPGs thought to increase cancer risk exclusively during adulthood are referred to as “adult‐onset” CPGs (aoCPGs).
Maria Rozo, Miriam A. Bornhorst, Angela J. Waanders, Sara Zarnegar‐Lumley, Ashwin Lakshman Koppayi, Lucy A. Godley   +5 more
wiley   +1 more source

Effect of a truncated mutant factor V on hemostatic function and embryonic development in mice

Scientific Reports
Factor V is an essential protein in the blood clotting process and plays a central role in secondary hemostasis. Its deficiency causes a rare inherited disorder characterized by episodes of severe bleeding, some of which can be life-threatening. Although
Andrea Miguel-Batuecas, Juan A. De Pablo-Moreno, Néstor Porras, Pablo Bermejo-Álvarez, Leopoldo González-Brusi, Luis J. Serrano, Javier M. De Pablo-Moreno, María José Sánchez, Mariano García-Arranz, Antonio Rodríguez-Bertos, Bilgimol Chumappumkal Joseph, Luis Revuelta, Antonio Liras   +12 more
doaj   +1 more source

NEWLY DIAGNOSED HEREDITARY FACTOR V DEFICIENCY IN A PATIENT PRESENTING WITH DEEP VEIN THROMBOSIS: A Rare Case

Hematology, Transfusion and Cell Therapy
Objective: Factor V (FV) is a crucial regulator of hemostasis, functioning as both a procoagulant and an anticoagulant glycoprotein within the coagulation cascade. In plasma, FV exists as an inactive precursor, which is activated by thrombin or factor Xa
Songül Beskisiz Dönen, Vehbi Demircan, Abdullah Karakuş, Mehmet Orhan Ayyıldız   +3 more
doaj   +1 more source

A neonatal presentation of factor V deficiency: A case report

BMC Pediatrics, 2007
Background Factor V deficiency is a rare autosomal recessive coagulation disorder. Awareness of presenting features and management is important to avoid bleeding complications associated with mortality and neurodisability.
Gadiraju Anjali, Eisenhut Michael, Chingale Amol, Liesner Ri   +3 more
doaj   +1 more source